Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512889 | 1.00 | PIK3CA (0.44) | PIK3CASLC22A12PTGS1PTGS2GAA | |
| SCHEMBL26135470 | 0.92 | PIK3CA (0.39) | PIK3CASLC22A12PTGS1PTGS2GAA | |
| SCHEMBL29969456 | 0.92 | PIK3CA (0.39) | PIK3CASLC22A12PTGS1PTGS2GAA | |
| SCHEMBL858551 | 0.83 | SLC22A12 (0.42) | PIK3CASLC22A12PTGS1PTGS2PIK3CD | |
| SCHEMBL26590469 | 0.80 | EGFR (0.32) | PIK3CAEGFR | |
| SCHEMBL21512874 | 0.76 | PIK3CA (0.39) | PIK3CASLC22A12EGFRALDH1A1 | |
| SCHEMBL21513770 | 0.76 | PIK3CA (0.41) | PIK3CASLC22A12PTGS1PTGS2GAA | |
| SCHEMBL29969077 | 0.76 | PIK3CA (0.41) | PIK3CASLC22A12PTGS1PTGS2GAA | |
| SCHEMBL29969088 | 0.76 | PIK3CA (0.39) | PIK3CASLC22A12EGFRALDH1A1 | |
| SCHEMBL21513218 | 0.74 | SLC22A12 (0.34) | PIK3CASLC22A12PTGS1PTGS2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | PIK3CA 480/4885SLC22A12 3581/4885PTGS1 3198/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | PIK3CA 480/4885SLC22A12 3581/4885PTGS1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.